FINWIRES · TerminalLIVE
FINWIRES
$ABBV

$ABBV

76 stories mentioning ABBVUpdated 3d ago

Every FINWIRES story that references ABBV, newest first.

What are analysts saying about ABBV?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on ABBV?

Research

Research Alert: CFRA Retains Buy Rating On Shares Of Abbvie Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $255, 15.8x our 2026 EPS view. This is above ABBV's 10-year historical forward P/E average of 12.1x, justified by its improving long-term growth prospects. We raise our 2026 EPS view to $14.17 from $14.02 to reflect the Q1 beat and raised expectations for the rest of the year. We keep our 2027 EPS view at $16.13. ABBV reported a strong start to 2026, with Q1 results surpassing expectations. Revenues reached $15B, a 12.4% increase, beating expectations due to the continued momentum in the Immunology and Neuroscience franchises. Adjusted EPS came in at $2.65, above the guidance midpoint despite an unfavorable impact from acquired IPR&D. We think the early data from the Amylin Analog (ABBV-295) showed promising weight loss results with good tolerability. With Phase 2 studies expected to begin in Q3 2026, we think updates should be closely followed as ABBV-295 could well position AbbVie in the highly lucrative obesity market with a potentially differentiated, non-incretin-based mechanism.

$ABBV
US Markets

AbbVie Raises 2026 Outlook Following First-Quarter Beat on Immunology Growth

AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected first-quarter results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs.Per-share adjusted earnings are expected at $14.08 to $14.28 for 2026, up from prior guidance of $13.96 to $14.16. The guidance includes $0.41 in expenses related to acquired in-process research and development and milestone expenses in the first quarter. The current consensus on FactSet is for non-GAAP EPS of $14.12.AbbVie now expects revenue of about $67.3 billion for the current year, an increase of $300 million, Chief Financial Officer Scott Reents said during an earnings call, according to a FactSet transcript. The Street is looking for $67.07 billion.The company's shares rose 0.9% in Wednesday trading. The stock has dropped 13% this year.For the March quarter, the company reported adjusted EPS of $2.65, up from $2.46 a year earlier and ahead of the Wall Street estimate of $2.59. Revenue climbed 12% to $15 billion, surpassing the estimate on FactSet for $14.72 billion."We are off to an excellent start in 2026, with first-quarter results exceeding our expectations," CEO Robert Michael said in a statement. "AbbVie's key growth drivers continue to deliver strong performance and support our enhanced full-year outlook."Global sales from the immunology portfolio rose 16% to $7.29 billion. Gains of 31% for Skyrizi and 23% for Rinvoq helped counter a 39% drop for Humira. In the neuroscience segment, revenue jumped 26% to $2.89 billion, while oncology portfolio sales eased 0.2% to $1.63 billion.Revenue in the aesthetics portfolio increased 7.6% to $1.19 billion.AbbVie projects adjusted EPS of $3.74 to $3.78 in the current quarter on revenue of $16.7 billion, including a foreign-exchange gain of 0.6%, Reents said on the call. Analysts project non-GAAP EPS of $3.75 on sales of $16.8 billion.Price: $199.39, Change: $+1.70, Percent Change: +0.86%

$ABBV
Research

Research Alert: Abbvie: Solid Q1 Bolstered By Immunology And Neuroscience, Eps Guidance Raised

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:AbbVie delivered strong Q1 2026 results with adjusted EPS of $2.65 (+7.7% Y/Y) slightly below the consensus of $2.67 due to $0.41 unfavorable impact from acquired IPR&D and milestones expense. Net revenues of $15.002B (+12.4% Y/Y) beat expectations by $280M, reflecting robust growth across key therapeutic areas. The successful transition from Humira to newer immunology assets continues to validate AbbVie's strategic positioning, with Skyrizi revenues of $4.483B (+30.9%) and Rinvoq revenues of $2.119B (+23.3%) substantially offsetting Humira's decline to $688M (-38.6%). The company raised its 2026 adjusted EPS guidance to $14.08-$14.28 from $13.96-$14.16, which includes the Q1 IPR&D impact. We believe the diversified growth platform demonstrates continued strength, with the immunology franchise generating $7.290B (+16.4%) and neuroscience portfolio delivering $2.875B (+26.0%). In our view, AbbVie's commitment to pipeline expansion through strategic investments positions the company well for sustained growth.

$ABBV
US Markets

Equity Futures Rise Ahead of Mega-Cap Tech Earnings, Fed Decision

US equity futures were pointing higher Wednesday as traders awaited the latest quarterly results of four mega-cap technology companies and the Federal Reserve's monetary policy decision.The Nasdaq was up 0.4% before the bell, while the S&P 500 and the Dow Jones Industrial Average rose 0.1% each. The indexes closed the previous trading session in the red.Tech giants Alphabet (GOOG, GOOGL), Microsoft (MSFT), Amazon (AMZN), and Meta Platforms (META) are scheduled to release quarterly results after the markets close, while AbbVie (ABBV) and General Dynamics (GD) will post before the bell, among others.The Fed's monetary policy committee will announce its latest decision on interest rates later in the day. Markets widely expect the central bank to keep its benchmark lending rate unchanged for a third consecutive meeting. Fed Chair Jerome Powell will hold a press conference at 2:30 pm ET."Investors will be listening closely for an updated assessment of economic conditions, particularly inflation, in the wake of the ongoing conflict overseas," Stifel said in a note. "A rising level of concern could signal a willingness to hold rates steady for a prolonged period of time or even open up the possibility of a rate hike, while any mention of a temporary or expected 'transitory' impact will likely bolster expectations for a potential return to rate cuts."The Senate Banking Committee is set to vote Wednesday on Trump's nominee for the next Fed chair, Kevin Warsh, Reuters reported.Treasury yields were trending upwards in premarket action, with the two-year rate advancing 1.7 basis points to 3.86% and the 10-year rate adding one basis point to 4.36%.Wednesday's economic calendar also has the weekly mortgage applications bulletin at 7 am ET. Data on durable goods orders for March and housing starts and permits reports for February and March are out at 8:30 am. The weekly EIA domestic petroleum inventories report posts at 10:30 am.West Texas Intermediate crude oil rose 3.4% to $103.32 a barrel before the opening bell, while Brent gained 2.9% to $114.35.US President Donald Trump has told aides to prepare for an extended blockade of Iran to pressure Tehran over its nuclear program, The Wall Street Journal reported, citing US officials. Trump believes resuming strikes on Iran or ending the conflict would carry higher risks than maintaining the US blockade of Iranian ports, which began recently, the report said.Mediators in Pakistan expect to get a revised proposal from Iran to end the war in the next few days, CNN reported, citing sources.The United Arab Emirates on Tuesday said it has decided to leave the Organization of the Petroleum Exporting Countries. The move would make the cartel "structurally weaker" as the UAE is one of the few OPEC members that have spare capacity, Rystad Energy said in a note.Shares of NXP Semiconductors (NXPI) and Seagate (STX) rose 18% each before the bell following their latest quarterly results. Starbucks (SBUX) was up 4.1% as the coffee giant raised its full-year outlook late Tuesday.Robinhood Markets (HOOD) plunged 11% after its quarterly results fell short of Wall Street's estimates overnight.Gold slipped 0.6% to $4,580 per troy ounce, while bitcoin gained 1.7% to $77,547.

Dow JonesNasdaq CompositeS&P 500$ABBV$AMZN$GD$GOOG$GOOGL$HOOD$META$MSFT$NXPI$SBUX$STX
Wire

AbbVie to Make $18 Million Milestone Payment to EvolveImmune Therapeutics After Nomination of Development Candidate

AbbVie (ABBV) partner EvolveImmune Therapeutics has nominated a development candidate for a next-generation cancer biotherapeutic, triggering a preclinical milestone payment of $18 million from AbbVie, the immuno-oncology company said Tuesday.The two companies entered into a collaboration and option-to-license agreement to develop multi-specific biologics for multiple targets in oncology in October 2024, according to a statement.Price: $198.10, Change: $+0.72, Percent Change: +0.37%

$ABBV
Wire

AbbVie Submits Application for Upadacitinib as Alopecia Areata Treatment to FDA

AbbVie (ABBV) submitted to the US Food and Drug Administration an application for upadacitinib's new indication as treatment for adult and adolescent patients with severe alopecia areata, the company said Tuesday.The company said it used data from a phase 3 trial of upadacitinib, also known as Rinvoq, to support the application. The trial met its primary endpoint of a severity of alopecia tool score of less than or equal to 20 at week 24, AbbVie said.Upadacitinib's safety profile in the trial was also consistent with previously announced study results, the company added.Price: $197.37, Change: $-0.03, Percent Change: -0.02%

$ABBV
Wire

Piper Sandler Adjusts Price Target on AbbVie to $294 From $299, Maintains Overweight Rating

AbbVie (ABBV) has an average rating of overweight and mean price target of $252.38, according to analysts polled by FactSet.Price: $201.71, Change: $+1.21, Percent Change: +0.60%

$ABBV
Wire

AbbVie to Build $1.4 Billion Manufacturing Campus in North Carolina

AbbVie (ABBV) said Wednesday it will invest $1.4 billion to construct a 185-acre AI-powered pharma manufacturing campus in Durham, North Carolina, as part of a $100 billion research and capital investment plan in the US.Construction will begin this year, with completion expected by the end of 2028, the company said, adding that the project will generate over 2,000 construction jobs.The site was selected for its local workforce and ability to support future expansion, the company said.Price: $202.92, Change: $-2.20, Percent Change: -1.07%

$ABBV
Wire

Street Color: AbbVie to Invest $1.4 Billion for New Pharmaceutical Manufacturing Campus in North Carolina

Street Color: AbbVie to Invest $1.4 Billion for New Pharmaceutical Manufacturing Campus in North Carolina

$ABBV
Research

Canaccord Genuity Initiates AbbVie at Buy With $262 Price Target

AbbVie (ABBV) has an average rating of overweight and mean price target of $255.37, according to analysts polled by FactSet.

$ABBV
Wire

Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says

Johnson & Johnson (JNJ) reported above-peer top-line growth in Q1 and a limited loss-of-exclusivity exposure, but that is already reflected in the company's premium multiple, BofA Securities said in a client note Wednesday.In its Q1 results, Johnson & Johnson did not provide any material research and development pipeline updates, with the investor call focusing on the Icotyde plaque psoriasis drug launch and reasons for perceived "softness" in MedTech, the BofA analysts said."Overall, 1Q offered nothing thesis changing," the analysts said.BofA said that the company's Tremfya drug has solidified its "number two" position in the drug target category, aided by subcutaneous Crohn's induction, with that benefit expected to neutralize when competitor AbbVie (ABBV) launches subcutaneous Skyrizi in 2027.The analysts updated their Tremfya peak sales estimate to $13 billion from $11 billion.BofA retained a neutral rating on the stock and increased its price target to $254 from $253.Price: $238.42, Change: $-1.68, Percent Change: -0.70%

$ABBV$JNJ
Wire

Evercore ISI Adjusts AbbVie Price Target to $232 From $233, Maintains Outperform Rating

AbbVie (ABBV) has an average rating of overweight and mean price target of $255.12, according to analysts polled by FactSet.Price: $204.75, Change: $-3.19, Percent Change: -1.53%

$ABBV
Research

Research Alert: CFRA Keeps Buy Rating On Shares Of Abbvie Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $255 from $275, 15.8x our 2026 EPS view. This is above ABBV's 10-year historical forward P/E average of 12.0x, justified by the company's improving long-term growth prospects. We lower our 2026 EPS forecast to $14.02 from $14.29 as we adjust our Q1 EPS estimate to $2.63 from $3.05. The company disclosed a new IPR&D and milestone expense of $744M last week related to collaborations, licensing agreements, and asset acquisitions, which will dilute Q1 EPS. We keep our 2026 EPS estimate at $16.13. The company is expected to report Q1 results before market open on April 29, when we expect to get more color on Q1 performance and expectations for the remainder of 2026.

$ABBV
Sectors

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks declined late Friday afternoon, with the NYSE Health Care Index falling 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 1.4%.The iShares Biotechnology ETF (IBB) shed 1.7%.In corporate news, AbbVie (ABBV) is expected to report Q1 earnings within its guidance range, but that may not be enough to improve sentiment toward the drugmaker, RBC Capital Markets said in a client note. The brokerage expects AbbVie to report per-share earnings of $2.59 for the first quarter, while the current consensus on FactSet is for non-GAAP EPS of $2.83. AbbVie shares were down 2.1%.Replimune (REPL) shares tumbled 19%. The company's biologics license application for vusolimogene oderparepvec to treat unresectable advanced cutaneous melanoma was rejected by the US Food and Drug Administration, the regulator said in a complete response letter.Abbott Laboratories (ABT) has been ordered by a jury in Chicago to pay $53 million in compensatory damages to a group of families related to four cases over its infant formula, the Chicago Tribune reported. The families accused the company of allegedly failing to inform them that its infant formula could develop a dangerous intestinal disease in premature infants, the report said. Abbott shares fell 2.7%.Organon (OGN) is closing in on a deal to be acquired by Sun Pharmaceutical Industries for $12 billion, The Economic Times reported. Organon shares surged 27%.

$ABBV$ABT$OGN$REPL
Sectors

Sector Update: Health Care

Health care stocks declined late Friday afternoon, with the NYSE Health Care Index falling 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 1.4%.The iShares Biotechnology ETF (IBB) shed 1.7%.In corporate news, AbbVie (ABBV) is expected to report Q1 earnings within its guidance range, but that may not be enough to improve sentiment toward the drugmaker, RBC Capital Markets said in a client note. The brokerage expects AbbVie to report per-share earnings of $2.59 for the first quarter, while the current consensus on FactSet is for non-GAAP EPS of $2.83. AbbVie shares were down 2%.

$ABBV
US Markets

AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says

AbbVie (ABBV) is expected to report first-quarter earnings within its guidance range, but that may not be enough to improve sentiment toward the drugmaker, RBC Capital Markets said in a Friday client note.The brokerage expects AbbVie to report per-share earnings of $2.59 for the first quarter, while the current consensus on FactSet is for non-GAAP EPS of $2.83.Earlier in April, AbbVie revised its first-quarter adjusted EPS outlook to a range of $2.56 to $2.60. The company said it expected a pre-tax charge of $744 million related to acquired in-process research and development and other expenses to negatively impact its bottom line by $0.41 a share."We think the bar is high for (AbbVie), and 'in-line' results may not be enough to turn the tide on the negative sentiment," RBC analyst Trung Huynh wrote in the note. "Unless the company delivers a clear beat, we see the current malaise persisting into (the second quarter of 2026)."AbbVie is scheduled to release its latest quarterly results on April 29.Sales of the company's immunology drugs, Skyrizi and Rinvoq, in the first quarter are tracking with consensus and guidance, according to RBC. The brokerage anticipates a "small" year-over-year decline in AbbVie's oncology segment, impacted by Inflation Reduction Act pricing erosion and decreasing volume for cancer drug Imbruvica.RBC forecasts the company to report revenue of $14.82 billion, while the Street is looking for $14.73 billion.The brokerage has an outperform rating on AbbVie's stock with a price target of $260.

$ABBV

Showing 61-76 of 76

Track with the FINWIRES app suite